UniQure Current Ratio 2013-2021 | QURE

UniQure current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
UniQure Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.69B $0.05B 15.06
2021-03-31 $0.28B $0.03B 8.80
2020-12-31 $0.26B $0.03B 9.47
2020-09-30 $0.29B $0.03B 8.62
2020-06-30 $0.32B $0.03B 10.71
2020-03-31 $0.35B $0.03B 12.89
2019-12-31 $0.38B $0.03B 12.15
2019-09-30 $0.41B $0.03B 14.33
2019-06-30 $0.19B $0.02B 8.07
2019-03-31 $0.21B $0.02B 9.51
2018-12-31 $0.24B $0.02B 11.85
2018-09-30 $0.24B $0.03B 7.56
2018-06-30 $0.26B $0.03B 8.36
2018-03-31 $0.15B $0.03B 5.48
2017-12-31 $0.16B $0.02B 8.47
2017-09-30 $0.09B $0.03B 3.64
2017-06-30 $0.11B $0.02B 4.82
2017-03-31 $0.12B $0.02B 6.04
2016-12-31 $0.14B $0.02B 6.34
2016-09-30 $0.17B $0.02B 7.33
2016-06-30 $0.20B $0.03B 7.92
2016-03-31 $0.21B $0.03B 7.17
2015-12-31 $0.23B $0.03B 8.48
2015-09-30 $0.25B $0.03B 9.27
2015-06-30 $0.21B $0.03B 8.40
2015-03-31 $0.05B $0.02B 3.15
2014-12-31 $0.08B $0.02B 4.68
2014-09-30 $0.09B $0.02B 6.04
2014-06-30 $0.11B $0.02B 6.82
2014-03-31 $0.11B $0.02B 5.83
2013-12-31 $0.04B $0.01B 2.65
2013-09-30 $0.05B $0.01B 3.93
2012-12-31 $0.00B $0.01B 0.20
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.313B $0.038B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76